<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="323">
  <stage>Registered</stage>
  <submitdate>29/08/2005</submitdate>
  <approvaldate>6/09/2005</approvaldate>
  <actrnumber>ACTRN12605000304639</actrnumber>
  <trial_identification>
    <studytitle>Bronchodilator response in COPD: absent or wrong method of measurement?</studytitle>
    <scientifictitle>Can a novel measure of acute bronchodilator responsiveness predict improvement in exercise capacity after four weeks treatment with tiotropium bromide in subjects with chronic obstructive pulmonary disease?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Chronic obstructive pulmonary disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Salbutamol (200mcg), by metered dose inhaler, plus tiotropium bromide (18mcg), by dry powder inhaler, on one occasion, or placebo metered dose inhaler plus placebo capsule, by dry powder inhaler, on one occasion
Tiotropium bromide, 18mcg/day for four weeks, open label.</interventions>
    <comparator>Placebo metered dose inhaler plus placebo capsule</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Correlation between acute bronchodilator response and improvement in exercise capacity after four weeks treatment with tiotropium bromide</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation between acute bronchodilator response and improvement in exertional dyspnea</outcome>
      <timepoint>After four weeks treatment with tiotropium bromide.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Moderate to severe chronic obstructive pulmonary disease, with FEV1 &lt; 60% predicted and FEV1/FVC&lt;70%</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Active and placebo drugs matched for appearance, prepared by independent researcher</concealment>
    <sequence>Random number generator in Microsoft Excel to determine sequence of treatment, no restrictions</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>5/01/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Woolcock Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Woolcock Institute of Medical Research</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Woolcock Institute of Medical Research</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Service</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Cheryl Salome</name>
      <address>PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95158383</phone>
      <fax>+61 2 95506115</fax>
      <email>cms@woolcock.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Wendy Taylor</name>
      <address>PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156578</phone>
      <fax>+61 2 95505865</fax>
      <email>wtaylor@woolcock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>